Vol 55, No 3 (2021)
Review Article
Published online: 2021-03-12

open access

Page views 1628
Article views/downloads 923
Get Citation

Connect on Social Media

Connect on Social Media

Trends in glioblastoma treatment research: an analysis of clinical trials and literature

Aleksander E. Łaba12, Piotr Ziółkowski1
Pubmed: 33710606
Neurol Neurochir Pol 2021;55(3):269-280.

Abstract

Introduction. Glioblastoma is the most common, and the most lethal, primary malignant brain tumour in adults. The aim of the study was to present a comprehensive, data-based review of glioblastoma treatment research, considering all clinical trials and peer-reviewed journal publications.

Materials and methods. Data regarding all glioblastoma clinical trials that was available on 7 August 2019 on ClinicalTrials.gov was analysed. Information on interventions’ mechanisms of action was obtained from AdisInsight. A PubMed search for ‘glioblastoma’ was performed in September 2019. Citation counts were gathered from Scopus. Custom software for obtaining and analyzing data was developed by the authors.

Results. 1,388 clinical trials on glioblastoma with a start date between 1979 and 2020 were identified. The distribution of glioblastoma clinical trial phases differs significantly from that of other high-mortality cancers. 526 unique interventions of clinical trials and 206 molecular targets have been isolated. 32,410 publications on glioblastoma have been found, the number having increased especially since 2006. Publications on identified treatment options comprised 32.2%. Publications on glioblastoma are cited on average 4.27 times per year. The average specificity of treatment options’ publications for glioblastoma is 6.9%.

Conclusions. Glioblastoma treatment options and their molecular targets can be quantitatively ranked according to their
scientific research output. To the best of our knowledge, no such registries have been elaborated before.

Article available in PDF format

View PDF Download PDF file

References

  1. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013; 15 Suppl 2: ii1–i56.
  2. Brodbelt A, Greenberg D, Winters T, et al. (UK) National Cancer Information Network Brain Tumour Group. Glioblastoma in England: 2007-2011. Eur J Cancer. 2015; 51(4): 533–542.
  3. Hansen S, Rasmussen BK, Laursen RJ, et al. Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014. J Neurooncol. 2018; 139(2): 479–489.
  4. Natukka T, Raitanen J, Haapasalo H, et al. Incidence trends of adult malignant brain tumors in Finland, 1990-2016. Acta Oncol. 2019; 58(7): 990–996.
  5. Sadetzki S, Zach L, Chetrit A, et al. Epidemiology of gliomas in Israel: a nationwide study. Neuroepidemiology. 2008; 31(4): 264–269.
  6. Dobes M, Khurana VG, Shadbolt B, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000-2008): Findings of a multicenter Australian study. Surg Neurol Int. 2011; 2: 176.
  7. Cote DJ, Ostrom QT, Gittleman H, et al. Glioma incidence and survival variations by county-level socioeconomic measures. Cancer. 2019; 125(19): 3390–3400.
  8. Muquit S, Parks R, Basu S. Socio-economic characteristics of patients with glioblastoma multiforme. J Neurooncol. 2015; 125(2): 325–329.
  9. Miranda-Filho A, Piñeros M, Soerjomataram I, et al. Cancers of the brain and CNS: global patterns and trends in incidence. Neuro Oncol. 2017; 19(2): 270–280.
  10. Lee CH, Jung KW, Yoo H, et al. Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc. 2010; 48(2): 145–152.
  11. Tamimi AF, Tamimi I, Abdelaziz M, et al. Epidemiology of Malignant and Non-Malignant Primary Brain Tumors in Jordan. Neuroepidemiology. 2015; 45(2): 100–108.
  12. Korja M, Raj R, Seppä K, et al. Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. Neuro Oncol. 2019; 21(3): 370–379.
  13. Chapman S, Azizi L, Luo Q, et al. Has the incidence of brain cancer risen in Australia since the introduction of mobile phones 29 years ago? Cancer Epidemiol . 2016; 42: 199–205.
  14. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014; 16(7): 896–913.
  15. Philips A, Henshaw DL, Lamburn G, et al. Brain Tumours: Rise in Glioblastoma Multiforme Incidence in England 1995-2015 Suggests an Adverse Environmental or Lifestyle Factor. J Environ Public Health. 2018; 2018: 7910754.
  16. Young JS, Chmura SJ, Wainwright DA, et al. Management of glioblastoma in elderly patients. J Neurol Sci. 2017; 380: 250–255.
  17. Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica. 2007; 114(2): 97–109.
  18. IJzerman-Korevaar M, Snijders TJ, de Graeff A, et al. Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review. J Neurooncol. 2018; 140(3): 485–496.
  19. Stensjøen AL, Solheim O, Kvistad KA, et al. Growth dynamics of untreated glioblastomas in vivo. Neuro Oncol. 2015; 17(10): 1402–1411.
  20. Starnoni D, Berthiller J, Idriceanu TM, et al. Returning to work after multimodal treatment in glioblastoma patients. Neurosurg Focus. 2018; 44(6): E17.
  21. Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016; 18(11): 1062–1071.
  22. Siegel R, Miller K, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019; 69(1): 7–34.
  23. National Cancer Institute (NIH). SEER Cancer Statistics. https://seer.cancer.gov/statfacts/ (2019 Sep 8).
  24. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987–996.
  25. Ostrom QT, Rubin JB, Lathia JD, et al. Females have the survival advantage in glioblastoma. Neuro Oncol. 2018; 20(4): 576–577.
  26. Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017; 18(6): e315–e329.
  27. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015; 5: 18046.
  28. Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017; 318(23): 2306–2316.
  29. Pham TM, Sikdar KC, Cheung WY, et al. Premature Mortality Due to Malignancies of the Central Nervous System in Canada, 1980-2010. Neuroepidemiology. 2018; 50(3-4): 195–200.
  30. Bianco J, Bastiancich C, Jankovski A, et al. On glioblastoma and the search for a cure: where do we stand? Cell Mol Life Sci. 2017; 74(13): 2451–2466.
  31. Aldape K, Zadeh G, Mansouri S, et al. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015; 129(6): 829–848.
  32. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6): 803–820.
  33. Paolillo M, Boselli C, Schinelli S. Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. Brain Sci. 2018; 8(1).
  34. Cihoric N, Tsikkinis A, Minniti G, et al. Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov. Radiat Oncol. 2017; 12(1): 1.
  35. Vanderbeek AM, Rahman R, Fell G, et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018; 20(8): 1034–1043.
  36. Zanders ED, Svensson F, Bailey DS. Therapy for glioblastoma: is it working? Drug Discov Today. 2019; 24(5): 1193–1201.
  37. Nieder C, Astner ST, Grosu AL. Glioblastoma research 2006-2010: pattern of citation and systematic review of highly cited articles. Clin Neurol Neurosurg. 2012; 114(9): 1207–1210.
  38. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 2010; 7(9): e1000326.
  39. United States National Library of Medicine. https://www.ncbi.nlm.nih.gov/pubmed.
  40. National Cancer Institute Thesaurus. ncit.nci.nih.gov/ncitbrowser (2019 Aug 15).
  41. Springer. AdisInsight. https://adisinsight.springer.com ( 2019 Sep 15).
  42. Falagas ME, Pitsouni EI, Malietzis GA, et al. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J. 2008; 22(2): 338–342.
  43. Elsevier. Scopus. https://www.scopus.com.
  44. Vito MRM. segmented: an R Package to Fit Regression Models with Broken-Line Relationships. http://cran.r-project.org/doc/Rnews/.
  45. Altman DG, Bland JM. How to obtain the confidence interval from a P value. BMJ. 2011; 343: d2090.
  46. Rich MW. Impact Factor Revisited. J Card Fail. 2017; 23(8): 579–580.
  47. Hirsch BR, Califf RM, Cheng SK, et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. JAMA Intern Med. 2013; 173(11): 972–979.
  48. Cohen JF, Korevaar DA, Wang J, et al. Should we search Chinese biomedical databases when performing systematic reviews? Syst Rev. 2015; 4: 23.



Neurologia i Neurochirurgia Polska